Table 1 Summary of pooled effect sizes of ABCG2 and SLC2A9 polymorphisms on gout and hyperuricemia

   OR₁ (AA versus CC)

16

4.10, 5.00

0.463

0.332, 0.616

5

39.2

3.24

2.39, 4.41

0.461

0.253, 0.883

   OR₂ (CA versus CC)

16

1.95, 2.26

5

62.9

1.64

1.47, 1.82

   OR₁ (TT versus CC)

8

0.0

3.86

2.30, 9.76

0.670

0.362, 0.978

   OR₂ (CT versus CC)

8

0.0

2.46

1.93, 3.18

   OR₁ (AA versus GG)

6

54.6

0.43

0.34, 0.55

0.547

0.262, 0.925

   OR₂ (GA versus GG)

6

54.9

0.64

0.56, 0.72

   OR₁ (AA versus CC)

3

67.2

2.25

1.80, 2.81

0.527

0.131, 0.940

   OR₂ (CA versus CC)

3

44.6

1.56

1.35, 1.80

   OR₁ (CC versus TT)

6

55.0

0.42

0.36, 0.49

0.520

0.317, 0.847

3

0.0

0.57

0.37, 0.87

0.474

0.092, 0.954

   OR₂ (TC versus TT)

6

0.0

0.65

0.58, 0.72

3

0.0

0.75

0.63, 0.89

   OR₁ (CC versus TT)

6

68.1

1.55

1.17, 2.06

0.512

0.087, 0.960

3

0.0

1.03

0.60, 1.79

0.463

0.021, 0.972

   OR₂ (TC versus TT)

6

45.2

1.29

1.07, 1.55

3

28.8

0.85

0.48, 1.50

   OR₁ (CC versus TT)

5

29.0

0.38

0.29, 0.50

0.400

0.179, 0.829

   OR₂ (TC versus TT)

5

0.0

0.69

0.62, 0.78

   OR₁ (GG versus AA)

3

0.0

0.61

0.20, 1.87

0.395

0.019, 0.963

2

40.0

0.36

0.28, 0.46

0.370

0.078, 0.872

   OR₂ (AG versus AA)

3

0.0

0.82

0.53, 1.27

2

49.4

0.67

0.59, 0.77

   OR₁ (TT versus CC)

3

NA^c

NA^c

   OR₂ (CT versus CC)

3

0.0

0.60

0.39, 0.94

   OR₁ (GG versus AA)

3

38.7

0.35

0.28, 0.46

0.401

0.163, 0.799

   OR₂ (AG versus AA)

3

8.6

0.65

0.57, 0.74

   OR₁ (CC versus TT)

3

0.0

0.44

0.34, 0.58

0.528

0.216, 0.942

   OR₂ (TC versus TT)

3

8.5

0.66

0.58, 0.76